Cómo citar
Baracaldo AyalaR. L., PeñaL., Gómez RodríguezO., NietoJ. F. P., López CorreaP., & MedinaR. P. (2020). Características histopatológicas del carcinoma colorrectal con inestabilidad microsatelital (IMS). Revista Repertorio De Medicina Y Cirugía, 29(1). https://doi.org/10.31260/RepertMedCir.v29.n1.2020.172

Autores/as

Rafael Leonardo Baracaldo Ayala
Residente Patología
Laura Peña
Omar Gómez Rodríguez
Residente de tercer año de patología Fundación Universitaria de Ciencias de la Salud- Hospital de San José de Bogotá
José Fernando Polo Nieto
Profesor asistente, Departamento de Patología Fundación Universitaria de Ciencias de la Salud- Hospital de San José de Bogotá
Patricia López Correa
Instructor asistente, Departamento de Patología Fundación Universitaria de Ciencias de la Salud- Hospital de San José de Bogotá
Rafael Parra Medina
Docente investigador asociado, Departamento de Patología, División de investigaciones, Fundación Universitaria de Ciencias de la Salud- Hospital de San José de Bogotá

Resumen

El carcinoma colorrectal es una de las neoplasias con mayor incidencia a nivel mundial. Algunos de los tipos de cáncer colorrectal tienen componente hereditario y asociación con defectos en la reparación génica a nivel replicacional por mutaciones en los genes encargados (MLH1, MSH2, MSH6 y PMS2) llamándose esto la inestabilidad microsatélite. Esta situación se acompaña de mayor predisposición a desarrollar carcinoma colorrectal y carcinomas extracolónicos que incluyen cáncer de estómago, endometrio, ovarios, tracto urinario, entre otros. Es importante, entonces, evaluar la presencia de la inestabilidad microsatélite a nivel histopatológico conociendo que hay algunos hallazgos que hacen sospechar la presencia de estas alteraciones genéticas, tales como la presencia de linfocitos intraepiteliales, infiltrado inflamatorio Crohn-like, el subtipo histológico y la localización. El objetivo de este artículo es revisar en detalle algunas características de las variables mencionadas, así como de resaltar la importancia de otras variables histopatológicas con impacto pronóstico.

Licencia

Citas

1 Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1(4):505-27.

2 Xiao H, Yoon YS, Hong SM, Roh SA, Cho DH, Yu CS, et al. Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am J Clin Pathol 2013;140(3):341-7.

3 Muller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch 2016;469(2):125-34.

4 Stigliano V, Sanchez-Mete L, Martayan A, Diodoro M, Casini B, Sperduti I, et al. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome. J Exp Clin Cancer Res 2014;33:1.

5 Sie AS, Mensenkamp AR, Adang EM, Ligtenberg MJ, Hoogerbrugge N. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Ann Oncol 2014;25(10):2001-7.

6 Tiwari AK, Roy HK, Lynch HT. Lynch syndrome in the 21st century: clinical perspectives. QJM 2016;109(3):151-8.

7 Alonso-Espinaco V, Giraldez MD, Trujillo C, van der Klift H, Munoz J, Balaguer F, et al. Novel MLH1 duplication identified in Colombian families with Lynch syndrome. Genet Med 2011;13(2):155-60.

8 Ueno H, Hashiguchi Y, Shimazaki H, Shinto E, Kajiwara Y, Nakanishi K, et al. Objective criteria for crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol 2013;139(4):434-41.

9 Cini G, Carnevali I, Quaia M, Chiaravalli AM, Sala P, Giacomini E, et al. Concomitant mutation and epimutation of the MLH1 gene in a Lynch syndrome family. Carcinogenesis 2015;36(4):452-8.

10 Koelzer VH, Steuer K, Gross UC, Zimmermann D, Paasinen-Sohns A, Mertz KD, et al. Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. Front Oncol 2016;6:252.

11 Funkhouser WK, Jr., Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 2012;14(2):91-103.

12 Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009;33(1):126-33.

13 Roseweir AK, McMillan DC, Horgan PG, Edwards J. Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treat Rev 2017;57:1-7.

14 Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 2001;158(2):527-35.

15 Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer 2007;43(3):624-31.

16 Takemoto N, Konishi F, Yamashita K, Kojima M, Furukawa T, Miyakura Y, et al. The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol 2004;34(2):90-8.

17 Jakubowska K, Kisielewski W, Kanczuga-Koda L, Koda M, Famulski W. Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. Oncol Lett 2017;14(6):6421-32.

18 Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008;84(4):981-7.

19 Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 2012;147(4):366-72.

20 Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41(17):2645-54.

21 Shibutani M, Maeda K, Nagahara H, Fukuoka T, Iseki Y, Matsutani S, et al. Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. In Vivo 2018;32(1):151-8.

22 Matsutani S, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, et al. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci 2018;109(4):966-79.

23 Harrison JC, Dean PJ, el-Zeky F, Vander ZR. Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis. Hum Pathol 1995;26(1):31-8.

24 Rozek LS, Schmit SL, Greenson JK, Tomsho LP, Rennert HS, Rennert G, et al. Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. J Natl Cancer Inst 2016;108(8).

25 Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenviron 2011;4(3):377-92.

26 Svennevig JL, Lunde OC, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984;49(3):375-7.

27 Kim JH, Kim KJ, Bae JM, Rhee YY, Cho NY, Lee HS, et al. Comparative validation of assessment criteria for Crohn-like lymphoid reaction in colorectal carcinoma. J Clin Pathol 2015;68(1):22-8.

28 Pyo JS, Sohn JH, Kang G. Medullary carcinoma in the colorectum: a systematic review and meta-analysis. Hum Pathol 2016;53:91-6.

29 Schneider NI, Langner C. Prognostic stratification of colorectal cancer patients: current perspectives. Cancer Manag Res 2014;6:291-300.

30 College of American Pathologist. Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum. 2017.

Ref Type: Generic

31 Benedix F, Schmidt U, Mroczkowski P, Gastinger I, Lippert H, Kube R. Colon carcinoma--classification into right and left sided cancer or according to colonic subsite?--Analysis of 29,568 patients. Eur J Surg Oncol 2011;37(2):134-9.

32 Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. Eur J Surg Oncol 2015;41(3):300-8.

33 Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127(2):385-94.

34 Kirsch R, Messenger DE, Riddell RH, Pollett A, Cook M, Al-Haddad S, et al. Venous invasion in colorectal cancer: impact of an elastin stain on detection and interobserver agreement among gastrointestinal and nongastrointestinal pathologists. Am J Surg Pathol 2013;37(2):200-10.

35 Messenger DE, Driman DK, Kirsch R. Developments in the assessment of venous invasion in colorectal cancer: implications for future practice and patient outcome. Hum Pathol 2012;43(7):965-73.

36 American Joint Committee on Cancer. Cancer Staging Manual. Octava edición. Chicago: Springer; 2017.
Ref Type: Generic

37 Zhang MR, Xie TH, Chi JL, Li Y, Yang L, Yu YY, et al. Prognostic role of the lymph node ratio in node positive colorectal cancer: a meta-analysis. Oncotarget 2016;7(45):72898-907.

38 Arnold A, Kloor M, Jansen L, Chang-Claude J, Brenner H, von WM, et al. The association between microsatellite instability and lymph node count in colorectal cancer. Virchows Arch 2017;471(1):57-64.

39 Belt EJ, te Velde EA, Krijgsman O, Brosens RP, Tijssen M, van Essen HF, et al. High lymph node yield is related to microsatellite instability in colon cancer. Ann Surg Oncol 2012;19(4):1222-30.

40 Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural Invasion is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. Am J Surg Pathol 2016;40(1):103-12.

41 Ozturk MA, Dane F, Karagoz S, Tural D, Selcukbiricik F, Demirelli F, et al. Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer? Hepatogastroenterology 2015;62(137):59-64.

42 Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: A retrospective cohort study. Int J Surg 2017;37:42-9.

43 Alotaibi AM, Lee JL, Kim J, Lim SB, Yu CS, Kim TW, et al. Prognostic and Oncologic Significance of Perineural Invasion in Sporadic Colorectal Cancer. Ann Surg Oncol 2017;24(6):1626-34.

44 Labalde M, Labrador FJ, Golitsin A, Pinto S, Carlin J, García-Parreño J. Tumor budding y el cáncer colorrectal. Rev Chil Cir 2014;66(6):556-61.

45 De SL, Palmans S, Sagaert X. Tumour budding in colorectal cancer: what do we know and what can we do? Virchows Arch 2016;468(4):397-408.

46 Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420-8.

47 Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour "budding" an an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40(2):127-32.

48 Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, et al. Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. Am J Surg Pathol 2015;39(10):1340-6.

49 Rieger G, Koelzer VH, Dawson HE, Berger MD, Hadrich M, Inderbitzin D, et al. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer. Histopathology 2017;70(7):1044-51.

50 Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 2010;46(15):2788-98.

51 Marginean EC, Melosky B. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Arch Pathol Lab Med 2018;142(1):17-25.

Descargas

La descarga de datos todavía no está disponible.
Coordinador Editorial

Leonardo Arismendy Rodriguez
jlarismendy@fucsalud.edu.co
Fundación Universitaria de Ciencias de la Salud - FUCS
Bogotá DC, Colombia
Dirección: Carrera 19 No. 8 A 32
Tel: (+571) 3538100 Ext. 2836

Asistente Editorial

Gloria Restrepo B.
revista.repertorio@fucsalud.edu.co
Fundación Universitaria de Ciencias de la Salud - FUCS
Bogotá DC, Colombia
Dirección: Carrera 19 No. 8 A 32
Tel: (+571) 3538100 Ext. 2836


Vigilada Mineducación

Sistema OJS 3 - Metabiblioteca |